SpydrBlade Flex used in novel bariatric endoscopic technique by leading US innovator
Positive Clinical Feedback on SpydrBlade™ in BEAM Procedures
Creo Medical Group plc (“Creo” or the “Group”), the medical device company specialising in advanced energy solutions for therapeutic endoscopy, today announces the clinical use of SpydrBlade Flex in Bariatric Endoscopic Antral Myotomy (“BEAM”) procedures, performed by Professor Christopher C. Thompson MD, a globally recognised pioneer in bariatric endoscopy and originator of the BEAM technique.
Professor Thompson successfully completed two BEAM procedures using SpydrBlade Flex and presented the results at Frontiers in Endoscopic Surgery (FES) 2026, a leading international forum for advanced and emerging endoscopic procedures.
Translating innovation from podium to practice
BEAM is a non-invasive endoscopic bariatric procedure that adapts principles from third-space endoscopy to selectively target the gastric antrum, reducing contractility and delaying gastric emptying to promote long term satiety and weight loss in obese patients.
The use of SpydrBlade Flex for BEAM procedures highlights the rapid evolution of endoscopic bariatric techniques and the capability of Creo’s products to deliver precision and control in complex submucosal environments.
In the procedures, SpydrBlade Flex was utilised to perform a precise full thickness antral myotomy, demonstrating its versatility across advanced third-space and bariatric endoscopic procedures.
Expanding the role of advanced energy in metabolic endoscopy
SpydrBlade Flex is powered by Creo’s CROMA™ Advanced Energy Platform, delivering adaptive bipolar radiofrequency and microwave energy to enable controlled cutting, dissection and haemostasis.
Endoscopic bariatric therapies such as BEAM are increasingly positioned as a minimally invasive option between pharmacological therapies and surgical intervention. As the field evolves towards approaches that modulate physiological function, advanced energy solutions are expected to play a central role in enabling safe and reproducible procedures.
Supporting global clinical leadership
Creo continues to collaborate with leading clinical innovators and centres of excellence to support the development and adoption of advanced endoscopic techniques.
Successful use of SpydrBlade Flex in BEAM further reinforces its role as a core component of Creo’s advanced GI portfolio, with the potential to support adoption across both established and emerging therapeutic endoscopy procedures.
Professor Thompson commented:
“BEAM represents a new direction in bariatric endoscopy, focusing on modulation of gastric physiology to achieve weight loss. The ability to perform precise submucosal dissection and controlled full thickness myotomy is critical to the success of this approach.
“SpydrBlade Flex is a gamechanger for the myotomy and provides a high level of precision and control during these steps, supporting both the efficiency and consistency of the procedure. Before having the SpydrBlade Flex device, performing full thickness myotomy during the BEAM procedure was daunting. SpydrBlade Flex offers us more precision, speed, and the ability to safely perform, teach and potentially democratize this procedure.”
Craig Gulliford, Chief Executive Officer of Creo Medical Group plc, commented:
“The use of SpydrBlade Flex in BEAM procedures highlights the role our products can play in enabling the next generation of therapeutic endoscopy.
“As new procedural categories emerge, we are focused on ensuring our advanced energy platform supports clinicians with the precision and flexibility required to safely adopt and scale these innovations and bring improved patient outcomes. This further strengthens our strategy of driving platform utilisation by expanding clinical applications and partnerships with leading innovators.”
Posted 05/05/2026
For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.
